Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers
NCT03164109Phase 1Completed
- Sponsor
- Galera Therapeutics, Inc.
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of avasopasem manganese in oral mucositis (OM) (3 arms), sponsored by Galera Therapeutics, Inc. Primary endpoint: Change in QT interval corrected for heart rate using the Fridericia formula at 24 hours. Started Aug 2017; status: completed.
02
Drugs
avasopasem manganese
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT03164109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164109.